ArticlePloS one2025
5-hydroxymethylcytosines from circulating cell-free DNA as noninvasive prognostic markers for gastric cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrognostic assessment plays a crucial role in guiding clinical management and treatment decisions for gastric cancer patients. The enrichment characteristics of 5-hydroxymethylcytosine (5hmC) in circulating cell-free DNA (cfDNA) has emerged as potential prognostic epigenetic markers.
methodsUsing 5hmC-Seal combined with next-generation sequencing (NGS), we profiled the genome-wide distribution of 5hmC in plasma cfDNA samples from 51 gastric cancer patients. Prognostic biomarkers were selected via random survival forest and Cox proportion hazards models, and a prognostic model was subsequently constructed.
resultsSeven prognostic biomarker genes were identified, and the 7-gene prognostic model demonstrated a concordance index (C-index) of 0.892 (95% CI = 0.786-0.998). Patients in the high risk group had a significantly worse overall survival (OS) than those in low-risk group (log-rank P = 0.00012). When the cfDNA 5hmC risk-score was integrated with the traditional clinical characteristics, the C-index increased from 0.819 (95% CI = 0.727-0.911) to 0.904 (95% CI = 0.853-0.955). Multivariate analysis adjusted for age, TNM stage, and chemotherapy confirmed that a high risk-score of cfDNA 5hmC model was an independent predictor of poor OS (hazard ratio [HR]=27.47, 95% CI = 3.28-230.25).
conclusioncfDNA 5hmC serves as an effective prognostic biomarker with high predictive value for the long-term survival in postoperative gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.